Glioblastoma multiforme (GBM): Clinical presentation, experimental animal models and novel treatments
Publication Date
July 2019
Location
LSU Health Medical Education Building
Document Type
Abstract
Start Date
26-7-2019 9:00 AM
End Date
26-7-2019 12:00 PM
Description
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low expected survival rates (12-15 months). Many reasons of the low survival rate include high system toxicity, acquired chemoresistance, and the low penetrance of the blood brain barrier by many anti-cancer drugs. Female nude athymic mice aged 6-8 weeks were injected U87 GBM cells that express a luciferase reporter into the left striatum of the brain to induce GBM. The mice were anesthetized with ketamine and xylazine, buprenorphine was administered for pain relief. Physiological monitoring by rectal temperature and body weight was used as well as the observation of seizures and abnormal gait or posture. Treatment groups are as follows: LAU – 0901, Avastin, LAU – 0901 + Avastin, Elovanoids, LAU – 0901 + Elovanoids, Elovanoids + Avastin, and a Vehicle (Saline) group. Treatments were administered starting on Day 13 after GBM implantation. In-vivo imaging was performed on days 13, 20, and 30 post-implantations to show how the cells divided and grew over time by use of bioluminescence and quantitative analysis. All treatment groups exhibit decreased tumor growth and increased overall survival compared to the vehicle. One mouse from the saline group died, while all mice of the treatment groups survived. The best combination of treatment was Elovanoids + Avastin, showing the highest rate of decreased tumor growth on Day 30. Future studies explore combining and comparing more treatments to target the cocktail that exhibits the best and most aggressive tumor fighting capabilities.
Recommended Citation
Summers, Julian D., "Glioblastoma multiforme (GBM): Clinical presentation, experimental animal models and novel treatments" (2019). Summer Research Internship Program. 32.
https://digitalscholar.lsuhsc.edu/srip/2019/undergrad/32
Glioblastoma multiforme (GBM): Clinical presentation, experimental animal models and novel treatments
LSU Health Medical Education Building
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low expected survival rates (12-15 months). Many reasons of the low survival rate include high system toxicity, acquired chemoresistance, and the low penetrance of the blood brain barrier by many anti-cancer drugs. Female nude athymic mice aged 6-8 weeks were injected U87 GBM cells that express a luciferase reporter into the left striatum of the brain to induce GBM. The mice were anesthetized with ketamine and xylazine, buprenorphine was administered for pain relief. Physiological monitoring by rectal temperature and body weight was used as well as the observation of seizures and abnormal gait or posture. Treatment groups are as follows: LAU – 0901, Avastin, LAU – 0901 + Avastin, Elovanoids, LAU – 0901 + Elovanoids, Elovanoids + Avastin, and a Vehicle (Saline) group. Treatments were administered starting on Day 13 after GBM implantation. In-vivo imaging was performed on days 13, 20, and 30 post-implantations to show how the cells divided and grew over time by use of bioluminescence and quantitative analysis. All treatment groups exhibit decreased tumor growth and increased overall survival compared to the vehicle. One mouse from the saline group died, while all mice of the treatment groups survived. The best combination of treatment was Elovanoids + Avastin, showing the highest rate of decreased tumor growth on Day 30. Future studies explore combining and comparing more treatments to target the cocktail that exhibits the best and most aggressive tumor fighting capabilities.
Comments
Mentors: Nicolas G Bazan, MD, PhD and Ludmila Belayev, MD, LSUHSC Neuroscience Department of Excellence